Weak Phase III data have dealt a blow to Vectura’s (LON:VEC) hopes of seeing Flutiform approved for use in chronic obstructive pulmonary disease (COPD) patients. Vectura shares fell as much as 10% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback